CEO Update: December 2021

CEO Update: December 2021

InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in process development work, published and presented INSB200™ data, and closed an additional institutional funding round. For additional...